EyePoint Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

EyePoint Pharmaceuticals şirketinin toplam hissedar öz sermayesi $218.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $300.9M ve $82.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$253.79m
Eşitlik	US$218.73m
Toplam yükümlülükler	US$82.18m
Toplam varlıklar	US$300.92m

Son finansal sağlık güncellemeleri

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06

Recent updates

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EYPT 'nin kısa vadeli varlıkları ( $268.5M ) kısa vadeli yükümlülüklerini ( $48.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: EYPT şirketinin kısa vadeli varlıkları ( $268.5M ) uzun vadeli yükümlülüklerini ( $33.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EYPT borçsuzdur.

Borcun Azaltılması: EYPT şirketinin 5 yıl önce borç/öz sermaye oranı 293.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EYPT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: EYPT serbest nakit akışı her yıl % 3.9 1.8 yıl yetecek nakit akışına sahip olacaktır.

EyePoint Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Recent updates

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of Durasert for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals, Inc. Announces Board Changes

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

New major risk - Revenue and earnings growth

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Management Changes

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Executive Vice-Chairman exercised options and sold US$430k worth of stock

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Senior VP & Chief Medical Officer exercised options and sold US$621k worth of stock

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Executive Vice-Chairman recently sold US$874k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Executive Vice-Chairman exercised options and sold US$470k worth of stock

EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Executive Vice-Chairman recently sold US$415k worth of stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Senior VP & Chief Medical Officer notifies of intention to sell stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Price target increased by 28% to US$39.29

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

EyePoint Pharmaceuticals, Inc. Announces Executive Changes

EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901

EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Consensus revenue estimates increase by 19%

Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy

Consensus revenue estimates increase by 13%

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Full year 2022 earnings: EPS misses analyst expectations

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

EyePoint Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 02, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

EyePoint Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022